share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K:诺和诺德-股票回购计划
美股SEC公告 ·  08/06 08:23
Moomoo AI 已提取核心信息
Novo Nordisk A/S, a leading global healthcare company, has successfully concluded its share repurchase program initiated on May 6, 2024. The program, which was part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024, aimed to repurchase B shares for up to DKK 2.2 billion between May 7 and August 5, 2024. As of the end date, the company has repurchased a total of 2,332,876 B shares at an average price of DKK 878.97, amounting to a transaction value of DKK 9,727,706,050. Following the completion of this phase, Novo Nordisk now holds 12,432,916 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. The company, founded in 1923 and headquartered in Denmark, is committed to defeating serious chronic diseases and employs approximately 66,000 people worldwide.
Novo Nordisk A/S, a leading global healthcare company, has successfully concluded its share repurchase program initiated on May 6, 2024. The program, which was part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024, aimed to repurchase B shares for up to DKK 2.2 billion between May 7 and August 5, 2024. As of the end date, the company has repurchased a total of 2,332,876 B shares at an average price of DKK 878.97, amounting to a transaction value of DKK 9,727,706,050. Following the completion of this phase, Novo Nordisk now holds 12,432,916 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. The company, founded in 1923 and headquartered in Denmark, is committed to defeating serious chronic diseases and employs approximately 66,000 people worldwide.
一家领先的全球医疗保健公司——诺和诺德A/S已经成功完成了于2024年5月6日启动的股票回购计划。该计划是大型200亿丹麦克朗回购计划的一部分,计划在2024年2月6日开始的12个月内进行,旨在在2024年5月7日至8月5日期间回购最多22亿丹麦克朗的b类股份。截至结束日期,公司已回购23328760亿股股票,平均价格为878.97丹麦克朗,交易金额为97,277,060,500丹麦克朗。完成此阶段后,诺和诺德现持有124329160亿股库藏股,占公司股本的0.3%。其总股本,包括库藏股,为44.65亿A类和b类股份。诺和诺德的股票在纳斯达克哥本哈根交易,并且其American Depositary Receipts在纽约证券交易所上市。这家成立于1923年、总部位于丹麦的公司致力于战胜严重的慢性疾病,全球拥有约66,000名员工。
一家领先的全球医疗保健公司——诺和诺德A/S已经成功完成了于2024年5月6日启动的股票回购计划。该计划是大型200亿丹麦克朗回购计划的一部分,计划在2024年2月6日开始的12个月内进行,旨在在2024年5月7日至8月5日期间回购最多22亿丹麦克朗的b类股份。截至结束日期,公司已回购23328760亿股股票,平均价格为878.97丹麦克朗,交易金额为97,277,060,500丹麦克朗。完成此阶段后,诺和诺德现持有124329160亿股库藏股,占公司股本的0.3%。其总股本,包括库藏股,为44.65亿A类和b类股份。诺和诺德的股票在纳斯达克哥本哈根交易,并且其American Depositary Receipts在纽约证券交易所上市。这家成立于1923年、总部位于丹麦的公司致力于战胜严重的慢性疾病,全球拥有约66,000名员工。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息